Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 7/20 | 0.52 |
| ▸ | KDR | P35968 | 5/20 | 0.52 |
| ▸ | SRC | P12931 | 5/20 | 0.52 |
| ▸ | TEK | Q02763 | 2/20 | 0.52 |
| ▸ | KIT | P10721 | 2/20 | 0.49 |
| ▸ | FLT3 | P36888 | 2/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
| ▸ | BTK | Q06187 | 3/20 | 0.48 |
| ▸ | EGFR | P00533 | 4/20 | 0.47 |
| ▸ | ITK | Q08881 | 3/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.44 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6430834 | 0.95 | LCK (0.53) | LCKKDRSRCTEKKIT | |
| SCHEMBL6433914 | 0.91 | LCK (0.49) | LCKKDRSRCTEKKIT | |
| SCHEMBL6431567 | 0.90 | LCK (0.57) | LCKKDRSRCTEKKIT | |
| SCHEMBL6431538 | 0.90 | LCK (0.53) | LCKKDRSRCTEKKIT | |
| Acetic Acid SCHEMBL6434178 | 0.88 | LCK (0.50) | LCKKDRSRCTEKKIT | |
| SCHEMBL7702573 | 0.87 | LCK (0.52) | LCKKDRSRCTEKKIT | |
| SCHEMBL7004695 | 0.87 | LCK (0.50) | LCKKDRSRCTEKKIT | |
| Acetic Acid SCHEMBL6430313 | 0.86 | LCK (0.50) | LCKKDRSRCTEKKIT | |
| SCHEMBL5802530 | 0.85 | LCK (0.54) | LCKKDRSRCTEKKIT | |
| SCHEMBL6430319 | 0.84 | LCK (0.49) | LCKKDRSRCTEKKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | LCK 1011/4885KDR 1166/4885SRC 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.